Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|1|2|135-136

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.1, Iss.2, 2004-04, pp. : 135-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thalidomide in multiple myeloma

By García-Sanz Ramón  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity

By Breitkreutz Iris   Anderson Kenneth C  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 7, 2008-07 ,pp. : 973-985

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide - most significant drug in decades for multiple myeloma?

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Thalidomide is effective when added to dexamethasone for the treatment of newly diagnosed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1527, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite